SYMPOSIA

MONDAY,

JUNE 26

10:40 - 11:55

SY01 - Precision Oncology: Aligning Innovation & Assessment to Address Patient Access Challenges

Location: Plenary Room (Hall C)
Sponsor: Bayer Pharmaceuticals
Abstract Summary: Precision oncology holds unprecedented promise for improving the outcomes of cancer patients but presents challenges to conventional HTA: rapid-paced innovation, small sample sizes, limitations on randomization, short-term outcomes, high unit costs, and diverse patient preferences. How can precision oncology and HTA evolve to optimize evidence-based access? This symposium convenes four stakeholder perspectives to discuss these challenges and ways to address them

MONDAY,

JUNE 26

16:00 - 17:15

SY02 - Value Creation And Efficiency Gains Through Capacity-Enhancing Innovations To Address Workforce Shortage.

Location: Plenary Room (Hall C)
Sponsor: Edwards Lifesciences
Abstract Summary: Continuous healthcare workforce shortages put increasing pressure on healthcare systems increasing patients backlog with considerable impact on morbidity and mortality.

Capacity-enhancing innovations enable access to innovative care while reducing burdens on healthcare providers and hospitals. Recognizing this value, measuring, and rewarding it, requires adaptive HTA methods to inform policy makers’ decisions. Evidence-based efficiency gains support such innovative technologies’ adoption

TUESDAY,

JUNE 27

09:25 - 10:40

SY03 - From Data to Health: Enhanced Evidence Methods and Practical Applications for HTA and Treatment Access in Prostate Cancer

Location: Plenary Room (Hall C)
Sponsor: Bayer HealthCare Pharmaceuticals, Inc.
Abstract Summary: Prostate cancer is a disease state with high prevalence and mortality but also rapid treatment innovation. As such, it is important for evidence generation methodologies to also evolve in characterizing treatment value for HTA. Enhanced methods for indirect treatment comparisons, preference studies, and population-level equity considerations, would support more holistic HTA and treatment access for men with prostate cancer.

TUESDAY,

JUNE 27

12:35 - 13:35

SY04 - Counting the cost – assessing the true value of investing in cancer treatments

Location: Plenary Room (Hall C)
Sponsor: Novartis Pharma AG
Abstract Summary: Join three leading experts in Health Technology Assessment (HTA) and patient advocacy to learn about innovative approaches to capturing the social value for people of health technologies and to broaden the scope of HTA, with a focus on Social Return on Investment (SROI) and what truly is valued by patients and wider society. The symposium will explore how to incorporate the social and economic impact of health technologies into HTA and assess their broader impact on population health and well-being.

HTAi 2023 ANNUAL MEETING